MannKind Stock Makes Moves on Milestone Payment

Short sellers have targeted MNKD stock

Digital Content Manager
Apr 1, 2019 at 9:58 AM
facebook twitter linkedin

Biopharmaceutical concern MannKind Corporation (NASDAQ:MNKD) is volatile today, after the company received a $12.5 million milestone payment from United Therapeutics (UTHR). The payment is part of a collaboration agreement -- worth up to $37.5 million in milestone payments for MNKD -- to develop and commercialize MNKD's hypertension treatment as a dry powder formula. After jumping 1.5% out of the gate,  the shares were last seen down 2.5% at $1.92.

The equity rallied hard off its December low of $0.94, and hit a six-month high of $2.34 on March 20. The shares have since pulled back below the $2 mark -- a 23.6% Fibonacci retracement of that recent surge, and a layer of resistance last June and October. The penny stock is still up 81.5% year-to-date, though. 

While analysts are relatively quiet on MannKind, the two brokerages that do follow the drugmaker give it "buy" and "strong buy" ratings. Plus the consensus 12-month target price of $3.50 represents an 82.3% premium to current levels, and sits in an area not seen since January 2018. 

Short sellers, meanwhile, have piled on their bearish bets. Short interest rose 5.4% in the latest reporting period, and now accounts for a solid 21.6% of the stock's available float, or 10 times the security's average daily trading volume.



Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!